Stockscreener 앱 받기
1.19
5.56%
-0.07
시간 외 거래:
1.19
전일 마감가:
$1.26
열려 있는:
$1.29
하루 거래량:
32,213
Relative Volume:
0.05
시가총액:
$8.24M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-11.85%
1개월 성능:
-12.74%
6개월 성능:
+84.90%
1년 성능:
+0.00%
1일 변동 폭
$1.18
$1.29
1주일 범위
$1.0601
$1.38
52주 변동 폭
$0.45
$3.80
Chromocell Therapeutics Corp Stock (CHRO) Company Profile
명칭
Chromocell Therapeutics Corp
전화
(917) 644-6313
주소
685 US HIGHWAY ONE, NORTH BRUNSWICK
CHRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRO
Chromocell Therapeutics Corp
|
1.19 | 8.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Chromocell Therapeutics Corp 주식(CHRO)의 최신 뉴스
Channel Therapeutics Faces Financial Uncertainty as Auditors Issue Going Concern Warning - Stock Titan
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Benzinga
Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks
Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewswire Inc.
Channel Therapeutics Corporation announced that it has received $0.25 million in funding -February 24, 2025 - Marketscreener.com
Channel Therapeutics secures $325,000 promissory note By Investing.com - Investing.com Australia
Channel Therapeutics secures $325,000 promissory note - Investing.com India
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
Wall Street-Heavily Traded - WDRB
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - StockTitan
Channel Therapeutics' Pain Treatment Breakthrough: Novel Nerve Block Outperforms Standard Care in Key Trial - StockTitan
Chromocell Therapeutics Announces Name Change to Channel Therapeutics Corporation and Provides Therapeutic Program Updates - Defense World
Chromocell Announces Name Change to 'Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - The Manila Times
Chromocell changes name to Channel Therapeutics, provides program updates - TipRanks
Channel Therapeutics Corporation Provides Therapeutic Program Update - Marketscreener.com
Chromocell Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com
Certain Warrants of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com
Chromocell Therapeutics Corporation announces an Equity Buyback for $0.25 million worth of its shares. - Marketscreener.com
Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - Marketscreener.com
Certain Common Stock of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com
Certain Series A Preferred Stock of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com
Chromocell Therapeutics Corporation announced that it expects to receive $0.75 million in funding - Marketscreener.com
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 - Marketscreener.com
Chromocell Therapeutics Corporation Announces Formal Launch of Eye Pain Treatment Program - Marketscreener.com
Chromocell Therapeutics Corporation announced that it has received $0.75 million in funding - Marketscreener.com
Chromocell Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Channel Therapeutics Advances Non-Opioid Pain Programs, Reports 96-Hour Drug Release Success - Stock Titan
Channel Therapeutics announces corporate restructuring By Investing.com - Investing.com Australia
Channel Therapeutics announces corporate restructuring - Investing.com India
Channel Therapeutics finalizes corporate restructuring By Investing.com - Investing.com Canada
Channel Therapeutics finalizes corporate restructuring - Investing.com
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times
Chromocell to Present at Upcoming Fall Investor Conferences - The Manila Times
Chromocell announces amendment to stock repurchase plan - MSN
Chromocell Therapeutics amends stock repurchase plan - TradingPedia
Chromocell Announces Amendment to Stock Repurchase Plan - The Manila Times
Chromocell boosts stock buyback plan to $750,000 - Investing.com
Chromocell Announces Amendment to Stock Repurchase Plan | CHRO Stock News - StockTitan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - GlobeNewswire
Another Delaware Publicly Traded Company Proposes A Nevada Move | Allen Matkins - JD Supra
Chromocell to Participate in Life Sciences Investor Forum September 19th - Yahoo Finance
CDMO Benuvia Appoints Terry Novak As New CEO - Pharmaceutical Online
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Tranche Update on Channel Therapeutics Corporation's Equity Buyback Plan announced on August 7, 2024. - Marketscreener.com
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - TradingView
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Chromocell Therapeutics Corp (CHRO) 재무 분석
Chromocell Therapeutics Corp (CHRO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):